Moderna COVID-19 vaccine passes FDA reviewers' test, but shares drop anyway GoodRx: COVID-19 worsening behavioral health conditions Biogen superspreader meeting spawned 300,000-plus U.S. coronavirus cases: study Ex-FDA chief Gottlieb pushes for antibody manufacturing scale up as 2021 pandemic 'insurance policy' Pfizer/BioNTech weren't alone: Moderna COVID-19 vaccine data targeted in EMA cyberattack Biopharma roundup: Lilly looks to $1B-plus COVID payout in 2020; Ex-FDA chief Gottlieb presses U.S. to boost antibody production Healthcare roundup: AHA, AMA call for health professionals to get vaccine Lilly eyes up to $2B in COVID-19 sales by year-end—plus revenue boosts in cancer, diabetes and more Featured Story | By Amirah Al Idrus Moderna’s COVID-19 vaccine is checking the boxes en route to an emergency nod. FDA staffers endorsed the shot as safe and effective in briefing documents published (PDF) on Tuesday, ahead of a COVID-19 vaccine advisory committee meeting scheduled for Thursday. read more |
| |
|---|
|
Top Stories By Paige Minemyer The pandemic is having a significant impact on people who were already living with behavioral health conditions prior to the spread of the virus, new data from GoodRx show. read more By Eric Sagonowsky Even as headlines raised alarms about coronavirus breaking out in the U.S. early this year, many events still went on—and Biogen's February management conference was one calamitous example. Just how calamitous? Researchers have now linked the event with hundreds of thousands of U.S. cases. read more By Fraiser Kansteiner The U.S. should invest in swiftly scaling up antibody production to buy itself an "insurance policy" against the pandemic in 2021, former FDA Commissioner Scott Gottlieb wrote in The Wall Street Journal. By paying companies to become contract manufacturers for the drugs, the U.S. could stockpile ingredients for a quick rollout next winter. read more By Angus Liu Looks like Pfizer and BioNTech’s COVID-19 vaccine was not the sole target of the recent cyberattack at the European Medicines Agency. Moderna said Monday that hackers also breached some documents from its pre-submission discussions about its COVID shot, mRNA-1273. read more By Eric Sagonowsky,Angus Liu,Kyle Blankenship,Conor Hale,Fraiser Kansteiner Eli Lilly is eyeing $1 billion-plus in COVID-19 sales this year. The U.S. should help boost manufacturing for antibodies like Lilly's and Regeneron's, ex-FDA chief Gottlieb said. Trump, Pence, Biden and Harris should all get vaccinated, NIAID director Fauci said. And researchers linked Biogen's superspreader conference to hundreds of thousands of COVID cases. read more By Healthcare Staff Follow along with the latest COVID-19 news straight from the Fierce Healthcare team. read more By Arlene Weintraub Eli Lilly's two COVID-19 treatments will add between $1 billion and $2 billion to sales this year, the company said, driving better-than-expected earnings. But the boost isn't just from COVID, but also from core Lilly products like diabetes drug Trulicity and breast cancer treatment Verzenio. read more |
